Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.89 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.89 |
| ▸ | HTR3A | P46098 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.58 |
| ▸ | HTR3B | O95264 | 3/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | HTR5A | P47898 | 1/20 | 0.58 |
| ▸ | DHFR | P00374 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30020071 | 1.00 | CHRNB2 (0.89) | CHRNB2CHRNA4HTR3AKDM4EHTR3E | |
| Hydrochloric Acid SCHEMBL4057198 | 0.98 | CHRNB2 (0.86) | CHRNB2CHRNA4HTR3AKDM4EHTR3E | |
| SCHEMBL6353476 | 0.94 | CHRNB2 (1.00) | CHRNB2CHRNA4HTR3AKDM4EHTR3E | |
| SCHEMBL8147076 | 0.83 | CHRNB2 (0.73) | CHRNB2CHRNA4HTR3AKDM4EDHFR | |
| SCHEMBL6352883 | 0.81 | HTR3A (1.00) | CHRNB2CHRNA4HTR3AKDM4EHTR3E | |
| SCHEMBL2280216 | 0.81 | AKR1C3 (0.73) | CHRNB2CHRNA4HTR3AKDM4EDHFR | |
| SCHEMBL2246876 | 0.80 | CHRNB2 (0.60) | CHRNB2CHRNA4HTR3AKDM4EDHFR | |
| SCHEMBL27454860 | 0.80 | CHRNB2 (0.58) | CHRNB2CHRNA4HTR3AKDM4EDHFR | |
| SCHEMBL28244687 | 0.79 | CHRNB2 (0.59) | CHRNB2CHRNA4KDM4EALDH1A1HTR1A | |
| SCHEMBL2418717 | 0.79 | HTR3E (0.61) | CHRNB2CHRNA4HTR3AKDM4EHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105712952-B | 2-substituted oxy-5-methylsulfonyl phenyl piperazine amide analogue and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| US-7615550-B2 | Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-7429585-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429585-B2 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | HOFFMANN-LA ROCHE (US) | 2008-09-30 | — | — | US | disclosed |
| CN-100400523-C | Substituted piperazines, (1,4) diaza * class and 2, 5-diazabicyclo (2.2.1) heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LTD (GB) | 2008-07-09 | — | — | CN | disclosed |
| CN-101070309-A | Substituted piperazines as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists, (1, 4) diazabi and 2, 5-diazabicyclo (2.2.1) heptanes | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | CN | disclosed |
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | JOLIDON SYNESE | 2007-09-20 | — | — | US | disclosed |
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | JOLIDON SYNESE | 2007-09-20 | — | — | US | disclosed |
| US-20040034219-A1 | Benzothiophene derivative compounds process of preparation and use thereof | LABORATORIOS VITA, S.A. (ES) | 2004-02-19 | — | — | US | disclosed |
| CN-1131211-C | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH AS (DK) | 2003-12-17 | — | — | CN | disclosed |
| EP-1337528-A2 | BENZOTHIOPHENE DERIVATIVE COMPOUNDS, PROCESS OF PREPARATION AND USE THEREOF | LABORATORIOS VITA, S.A. (ES) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002044170-A2 | BENZOTHIOPHENE DERIVATIVE COMPOUNDS, PROCESS OF PREPARATION AND USE THEREOF | LABORATORIOS VITA, S.A. (ES) | 2002-06-06 | — | — | WO | disclosed |
| EP-0802173-B1 | Process for producing heterocylic aromatic amine or arylamine | TOSOH CORP (JP) | 2001-12-19 | — | — | EP | disclosed |
| CN-1277604-A | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH AS (DK) | 2000-12-20 | — | — | CN | disclosed |
| EP-1027336-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2000-08-16 | — | — | EP | disclosed |
| US-5929281-A | REACTING A HETROCYCLIC AROMATIC HALIDE WITH AN AMINE COMPOUND IN PRESENCE OF A BASE USING A TRI-TERT-BUTYLPHOSPHINE AND PALLADIUM COMPOUND CATALYST TO FORM HETEROCYCLIC AROMATIC AMINE COMPOUNDS | TOSOH CORPORATION (JP) | 1999-07-27 | — | — | US | disclosed |
| WO-1999021834-A1 | HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 1999-05-06 | — | — | WO | disclosed |
| EP-0802173-A1 | Process for producing heterocylic aromatic amine or arylamine | Tosoh Corporation (JP) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219207-A1 | Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups | GRIK5, GRM5, GRIN2C | CHRNB2 666/4885CHRNA4 270/4885HTR3A 168/4885 |
| US-20040034219-A1 | Benzothiophene derivative compounds process of preparation and use thereof | TPH1, HTR1A, HTR5A | CHRNB2 519/4885CHRNA4 250/4885HTR3A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.